Please login to the form below

Not currently logged in
Email:
Password:

Glide Pharma appoints Mark Carnegie-Brown as CEO

Was formerly CEO of Evolutec and Aenova

Glide Pharma Mark Carnegie-BrownDr Mark Carnegie-Brown has joined Glide Pharma as CEO.

He brings more than 25 years of experience in the healthcare and life sciences industry to Glide - a development and device company focused on the needle-free administration of solid dose formulations.

His past experience includes five years as CEO of protein drug development company Evolutec from 2003 to 2008 and a year as CEO of contract manufacturing organisation Aenova from 2008 to 2009.

He also served as UK and Northern Europe managing director at Elsevier Health Sciences from 2009 to 2011 and managing director of Carbon Fibre Technologies International from November 2011.

“His research and commercial experience, and in particular his expertise in building successful clinical and manufacturing programmes, will prove invaluable as Glide scales up its capabilities and advances the development of its in-house programmes,” said Mark Kirby, chairman of Glide Pharma.

8th March 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...